Cargando…
Arketamine for cognitive impairment in psychiatric disorders
Cognitive impairment has been observed in patients with various psychiatric disorders, including schizophrenia, major depressive disorder (MDD), and bipolar disorder (BD). Although modern therapeutic drugs can improve certain symptoms (i.e., psychosis, depression) in these patients, these drugs have...
Autor principal: | Hashimoto, Kenji |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9925943/ https://www.ncbi.nlm.nih.gov/pubmed/36786865 http://dx.doi.org/10.1007/s00406-023-01570-5 |
Ejemplares similares
-
Molecular mechanisms underlying the antidepressant actions of arketamine: beyond the NMDA receptor
por: Wei, Yan, et al.
Publicado: (2021) -
A role of splenic heme biosynthesis pathway in the persistent prophylactic actions of arketamine in lipopolysaccharide-treated mice
por: Ma, Li, et al.
Publicado: (2023) -
Extracellular vesicle approach to major psychiatric disorders
por: Oraki Kohshour, Mojtaba, et al.
Publicado: (2022) -
Role of the gut microbiome in three major psychiatric disorders
por: Borkent, Jenny, et al.
Publicado: (2022) -
Editorial: Cognitive Enhancement in Psychiatric Disorders
por: Sumiyoshi, Tomiki, et al.
Publicado: (2019)